The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in ...

Background. A 48-year-old man presented with diarrhea, flushing, abdominal pain and weight loss of 10 kg over a 6-month period. He subsequently developed dyspnea on exertion. Diagnosis. Carcinoid ...

Appendix cancer is a rare and often overlooked type ... It can also present in other forms, including carcinoid tumours, mucinous adenocarcinomas, and peritoneal cancer. Symptoms often mimic ...

A 61-year-old patient with no relevant medical or family history presented with a 2 month history of refractory dry cough that led to the diagnosis of typical carcinoid tumor of the lung ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...